by admin | Jun 30, 2020 | Funding
Novo Ventures, part of Novo Holdings, today announced that it has led the $55 million (£44 million) Series B financing in NodThera, a UK and US based clinical stage biotechnology company developing a new class of medicines to treat diseases driven by chronic...
by admin | Jun 30, 2020 | Funding
Solvias Completes Agreement with Strategic Healthcare Investors to Advance Expansion Global Pharmaceutical Laboratory Services Company Appoints Two Seasoned Industry Executives to Board of Directors – Solvias Completes Agreement with Strategic Healthcare...
by admin | Dec 2, 2019 | Clinical Trials
BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are...
